Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma

BACKGROUND: Chemoradiotherapy alone is the standard treatment for locally advanced squamous cell anal carcinoma (SCAC). However, up to 50% of patients will experience recurrence; thus, there is a need for new treatments to improve outcomes. Modified docetaxel, cisplatin and 5-fluorouracil (mDCF) is...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Stefano, Boustani, Jihane, Vernerey, Dewi, Vendrely, Véronique, Evesque, Ludovic, Francois, Eric, Quero, Laurent, Ghiringhelli, Francois, de la Fouchardière, Christelle, Dahan, Laëtitia, Bouché, Oliver, Chibaudel, Benoist, Hajbi, Farid El, Vernet, Chloé, Rebucci-Peixoto, Magali, Feuersinger, Alexandra, Maritaz, Christophe, Borg, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472525/
https://www.ncbi.nlm.nih.gov/pubmed/36119522
http://dx.doi.org/10.3389/fonc.2022.918499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472525/
https://www.ncbi.nlm.nih.gov/pubmed/36119522
http://dx.doi.org/10.3389/fonc.2022.918499

Ejemplares similares